<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The aim of this study was to define the effects of unmodified niacin on basal <z:chebi fb="23" ids="18059">lipids</z:chebi> and <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> and on the plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> response to a fatty meal--postprandial or alimentary <z:mp ids='MP_0001548'>lipemia</z:mp>--in individuals with low levels of <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) and <z:mpath ids='MPATH_458'>normal</z:mpath> fasting cholesterol and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> concentrations (normolipidemic <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e>, isolated low <z:chebi fb="0" ids="47775">HDL-C</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Twenty-eight normolipidemic men (total plasma cholesterol concentration [TC] &lt; 230 mg/dL [&lt; 6 mmol/L], plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> [Tg] &lt; 250 mg/dL [2.75 mmol/L]) with low plasma concentrations of <z:chebi fb="0" ids="47775">HDL-C</z:chebi> were randomly assigned to increasing doses of crystalline niacin (up to 3,000 mg/d) or no drug for 12 weeks, then crossed over to the alternate regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Outcome measures included changes in plasma <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> and alimentary <z:mp ids='MP_0001548'>lipemia</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Fifteen participants completed the study </plain></SENT>
<SENT sid="4" pm="."><plain>Mean baseline <z:chebi fb="0" ids="47775">HDL-C</z:chebi> +/- SD was 31.7 +/- 6.2 mg/dL (0.82 +/- 0.16 mmol/L) </plain></SENT>
<SENT sid="5" pm="."><plain>Mean baseline TC, plasma concentration of <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>), and Tg were 192 +/- 29.4 mg/dL (4.97 +/- 0.76 mmol/L), 123 +/- 27 mg/dL (3.17 +/- 0.69 mmol/L), and 197 +/- 75 mg/dL (2.17 +/- 0.83 mmol/L), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Unmodified niacin treatment resulted in significant (P &lt; 0.001) reductions of 14% in TC (to 165 mg/dL, 4.26 mmol/L), 40% in Tg (to 119 mg/dL, 1.31 mmol/L), and 18% in <z:chebi fb="0" ids="47774">LDL-C</z:chebi> (to 101 mg/dL, 2.60 mmol/L) and significant increases of 30% in <z:chebi fb="0" ids="47775">HDL-C</z:chebi> (to 42 mg/dL, 1.07 mmol/L), 100% in HDL2 cholesterol (from 5 mg/dL to 9 mg/dL, 0.12 mmol/L to 0.24 mmol/L), and 21% in HDL3 cholesterol (from 27 mg/dL to 33 mg/dL, 0.70 mmol/L to 0.85 mmol/L) </plain></SENT>
<SENT sid="7" pm="."><plain>Unmodified niacin treatment reduced alimentary <z:mp ids='MP_0001548'>lipemia</z:mp> by 45% (P &lt; 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Crystalline niacin effectively raises <z:chebi fb="0" ids="47775">HDL-C</z:chebi>, lowers <z:chebi fb="0" ids="47774">LDL-C</z:chebi>, and reduces alimentary <z:mp ids='MP_0001548'>lipemia</z:mp> in patients with isolated low <z:chebi fb="0" ids="47775">HDL-C</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>However, many patients have difficulty tolerating the drug, and supervision may be required to sustain patient compliance and avoid toxicity </plain></SENT>
</text></document>